We feel now is a pretty good time to analyse TuHURA Biosciences, Inc.'s (NASDAQ:HURA) business as it appears the company may be on the cusp of a considerable accomplishment. TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms. With the latest financial year loss of US$29m and a trailing-twelve-month loss of US$19m, the US$201m market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on TuHURA Biosciences' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

View our latest analysis for TuHURA Biosciences

TuHURA Biosciences is bordering on breakeven, according to some American Biotechs analysts. They expect the company to post a final loss in 2026, before turning a profit of US$14m in 2027. Therefore, the company is expected to breakeven roughly 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 65%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving TuHURA Biosciences' growth isn’t the focus of this broad overview, but, bear in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

One thing we would like to bring into light with TuHURA Biosciences is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag.

Next Steps:

There are too many aspects of TuHURA Biosciences to cover in one brief article, but the key fundamentals for the company can all be found in one place – TuHURA Biosciences' company page on Simply Wall St. We've also compiled a list of relevant factors you should look at:

1. Valuation: What is TuHURA Biosciences worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether TuHURA Biosciences is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on TuHURA Biosciences’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.